ROCURONIUM BROMIDE INJECTION 10 MG — DIN 02517744
ROCURONIUM BROMIDE : 10 MG · HIKMA CANADA LIMITED · SOLUTION · wholesale supply in Canada
Health Canada status: MARKETED
What is ROCURONIUM BROMIDE INJECTION?
ROCURONIUM BROMIDE INJECTION 10 MG contains ROCURONIUM BROMIDE : 10 MG. It is listed in the Health Canada Drug Product Database under DIN 02517744, held by HIKMA CANADA LIMITED, supplied as SOLUTION for INTRAVENOUS administration. Health Canada currently lists it as marketed, status dated 29-Sep-2023. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is ROCURONIUM BROMIDE INJECTION used for?
Rocuronium Bromide Injection (rocuronium bromide) is indicated as an adjunct to general anesthesia to facilitate routine endotracheal intubation or rapid sequence (initiated at 60 - 90 seconds post - administration) intubation to provide skeletal muscle relaxation during surgery or mechanical ventilation.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Is there a generic Rocuronium Bromide in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
10 holders have a Canadian DIN containing Rocuronium Bromide, across 12 DINs, of which 6 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| SANDOZ CANADA INCORPORATED | 2 | 1 | ROCURONIUM BROMIDE INJECTION, ROCURONIUM BROMIDE INJECTION SDZ | Sourceable in Canada |
| AURO PHARMA INC | 1 | 1 | ROCURONIUM BROMIDE INJECTION | Sourceable in Canada |
| EUGIA PHARMA INC. | 1 | 1 | ROCURONIUM BROMIDE INJECTION | Sourceable in Canada |
| HIKMA CANADA LIMITED | 1 | 1 | ROCURONIUM BROMIDE INJECTION | Sourceable in Canada |
| JAMP PHARMA CORPORATION | 1 | 1 | ROCURONIUM BROMIDE INJECTION | Sourceable in Canada |
| JUNO PHARMACEUTICALS CORP. | 1 | 1 | ROCURONIUM BROMIDE INJECTION | Sourceable in Canada |
| OMEGA LABORATORIES LIMITED | 2 | 0 | INJECTABLE ROCURONIUM BROMIDE, ROCURONIUM BROMIDE INJECTION | No marketed DIN |
| MERCK CANADA INC | 1 | 0 | ZEMURON | No marketed DIN |
| PFIZER CANADA ULC | 1 | 0 | ROCURONIUM BROMIDE INJECTION | No marketed DIN |
| STERIMAX INC | 1 | 0 | ROCURONIUM BROMIDE INJECTION | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 10 MG |
|---|---|
| Dosage form | SOLUTION |
| Route | INTRAVENOUS |
| Pack configuration (monograph) | null |
| Storage | null |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
Substance and classification
| Active substance | Rocuronium Bromide |
|---|---|
| ATC code | M03AC09 |
| AHFS class | 12:20.20 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02517744 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2517744 |
| Brand name | ROCURONIUM BROMIDE INJECTION |
| Generic / active ingredient | ROCURONIUM BROMIDE : 10 MG |
| Market authorization holder | HIKMA CANADA LIMITED |
| Health Canada schedule | Prescription |
| ATC code | M03AC09 |
| ATC anatomical main group | M — Musculo-skeletal system |
| ATC therapeutic subgroup | M03AC |
| Current status | MARKETED |
| Status date | 29-Sep-2023 |
| Original market date | 2023-09-29 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
Is Rocuronium Bromide in shortage in Canada?
A Canadian shortage report is on file for a product containing this molecule: Active — reported by JUNO PHARMA CANADA INC., last seen 04 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
6 of 12 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| ROCURONIUM BROMIDE INJECTION | 10 MG | SOLUTION | JUNO PHARMACEUTICALS CORP. | MARKETED | 02469774 |
| ROCURONIUM BROMIDE INJECTION | 10 MG | SOLUTION | AURO PHARMA INC | MARKETED | 02498820 |
| ROCURONIUM BROMIDE INJECTION | 10 MG | SOLUTION | EUGIA PHARMA INC. | MARKETED | 02528657 |
| ROCURONIUM BROMIDE INJECTION | 10 MG | SOLUTION | SANDOZ CANADA INCORPORATED | MARKETED | 02318415 |
| ROCURONIUM BROMIDE INJECTION | 10 MG | SOLUTION | JAMP PHARMA CORPORATION | MARKETED | 02529831 |
| INJECTABLE ROCURONIUM BROMIDE | 10 MG | SOLUTION | OMEGA LABORATORIES LIMITED | CANCELLED PRE MARKET | 02539489 |
| ROCURONIUM BROMIDE INJECTION | 10 MG | SOLUTION | STERIMAX INC | APPROVED | 02442752 |
| ROCURONIUM BROMIDE INJECTION | 10 MG | SOLUTION | PFIZER CANADA ULC | CANCELLED POST MARKET | 02318121 |
| ROCURONIUM BROMIDE INJECTION | 10 MG | SOLUTION | OMEGA LABORATORIES LIMITED | CANCELLED POST MARKET | 02382415 |
| ROCURONIUM BROMIDE INJECTION SDZ | 10 MG | SOLUTION | SANDOZ CANADA INCORPORATED | CANCELLED PRE MARKET | 02390566 |
2 · Same class — other molecules in ATC M03AC
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Rocuronium Bromide | INJECTABLE ROCURONIUM BROMIDE · ROCURONIUM BROMIDE INJECTION · ROCURONIUM BROMIDE INJECTION SDZ · ZEMURON | 12 | 6 | Yes |
| Cisatracurium | AJ-CISATRACURIUM · CISATRACURIUM BESYLATE INJECTION · CISATRACURIUM BESYLATE INJECTION (PRESERVATIVE-FREE) · CISATRACURIUM BESYLATE INJECTION MULTI-DOSE · +6 more | 13 | 1 | Yes |
| Pancuronium | PANCURONIUM BROMIDE - LIQ IV 1MG/ML · PANCURONIUM BROMIDE - LIQ IV 2MG/ML · PANCURONIUM BROMIDE 1MG/ML · PANCURONIUM BROMIDE 2MG/ML · +2 more | 6 | 0 | Not in Canada |
| Atracurium | ATRACURIUM - (FOR SINGLE DOSE ) · ATRACURIUM - (FOR MULTIPLE DOSE VIAL - WITH PRESERVATIVE) · ATRACURIUM BESYLATE INJECTION · TRACRIUM | 6 | 0 | Not in Canada |
| Vecuronium | NORCURON INJ 10MG/VIAL · VECURONIUM BROMIDE FOR INJECTION | 4 | 0 | Not in Canada |
| Mivacurium Chloride | MIVACRON | 1 | 0 | Not in Canada |
| Gallamine | FLAXEDIL INJ 20MG/ML | 1 | 0 | Not in Canada |
| Doxacurium Chloride | NUROMAX | 1 | 0 | Not in Canada |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC M03A
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| M03AX | Botulinum Toxin | 16 | 12 |
| M03AB | Suxamethonium | 9 | 3 |
| M03AA | Dimethyltubocurarine · Tubocurarine | 3 | 0 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.